Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2016

View Archived Issues

Light-activated quantum dots show promise as phototherapy for multidrug-resistant infections

Oxeia Biopharmaceuticals develops OXE-103 for concussion

Lysyl oxidase identified as a factor in thrombosis risk

FDA approves Botox for the treatment of lower limb spasticity in adults

FDA clears IND application for Agenus' anti-CTLA-4 and anti-GITR antibodies

GSK discontinues development of alitretinoin in U.S.

Phase II results indicate sustained expression with AAT deficiency gene therapy

FDA grants orphan drug designation to TRACON's anti-endoglin antibody

Broad Institute Genomic Services and Takeda partner to expand genomic insight into Ninlaro

Genentech and Xenon Pharmaceuticals patent Nav1.7 channel blockers

Immunocore's IMCgp-100 gets FDA orphan drug designation for uveal melanoma

Incyte discloses KDM1A inhibitors

ST Pharm presents tankyrase-1 inhibitors

Pharmacyclics reports BTK inhibitors

Takeda's H. influenzae type b conjugate vaccine approved in Japan

Bonviva tablet approved in Japan for the treatment of osteoporosis

bioTheranostics to spin out from bioMerieux

Apollo Therapeutics Fund established to advance preclinical drug R&D at U.K. universities

Expanded FDA approvals for Opdivo + Yervoy and single-agent Opdivo in melanoma

Shire's acquisition of Dyax complete

Merck & Co. studies [11C]MK-6884 as PET imaging agent

FDA grants orphan drug designation to mutant KIT inhibitor for mastocytosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...